Silo Pharma (SILO) has entered into a service agreement with medical technology provider Resyca BV for a drug-device study of the formulation-specific microchip-based nasal spray system used in its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder. The Company is currently conducting two additional SPC-15 studies: an IND-enabling GLP compliant toxicology and toxicokinetics study, and an FDA requested 7-day safety and toxicology large animal study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Silo Pharma Completes Public Offering, Raises $1.56 Million
- Silo Pharma prices 3.3M shares at 60c in public offering
- Silo Pharma engages Veloxity Labs for bioanalysis supporting SPC-15
- Silo Pharma enters agreement with Frontage Laboratories for SPC-15 study
- Silo Pharma announces results for its preclinical study on SP-26